Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and Azacitidine in Post-Transplant MRD+ AML
NCT06066905Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tucidinostat in acute myeloid leukemia (AML), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Relapse-Free Survival at 6 months. Started Oct 2023; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06066905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066905.